' Akciju kurss '

Datums	BARD1 Life Sciences Akciju kurss
21.02.2022.	1,03 undefined
18.02.2022.	1,06 undefined

Datums	BARD1 Life Sciences Apgrozījums	BARD1 Life Sciences EBIT	BARD1 Life Sciences Peļņa
2021	510 980,00 undefined	-6,59 milj. undefined	-11,15 milj. undefined
2020	98 390,00 undefined	-2,33 milj. undefined	-3,25 milj. undefined
2019	8730,00 undefined	-1,77 milj. undefined	-1,72 milj. undefined
2018	7210,00 undefined	-1,92 milj. undefined	-1,82 milj. undefined
2017	4200,00 undefined	-2,59 milj. undefined	-2,60 milj. undefined
2016	0 undefined	-130 000,00 undefined	-2,84 milj. undefined
2015	0 undefined	0 undefined	0 undefined
2014	0 undefined	0 undefined	0 undefined
2013	10 000,00 undefined	-610 000,00 undefined	-10,52 milj. undefined
2012	300 000,00 undefined	-590 000,00 undefined	-10,45 milj. undefined
2011	200 000,00 undefined	-1,03 milj. undefined	-1,56 milj. undefined
2010	1,46 milj. undefined	480 000,00 undefined	-1,61 milj. undefined
2009	6,93 milj. undefined	5,78 milj. undefined	3,76 milj. undefined
2008	5,88 milj. undefined	4,85 milj. undefined	3,16 milj. undefined
2007	30 000,00 undefined	700 000,00 undefined	-11,09 milj. undefined
2006	190 000,00 undefined	-3,52 milj. undefined	-10,22 milj. undefined
2005	370 000,00 undefined	-2,27 milj. undefined	-3,13 milj. undefined
2004	630 000,00 undefined	-690 000,00 undefined	-1,13 milj. undefined
2003	1,28 milj. undefined	-580 000,00 undefined	-1,34 milj. undefined
2002	2,25 milj. undefined	-30 000,00 undefined	-180 000,00 undefined

	Apgrozījums	EBIT	Peļņa
2002	2,25 milj. AUD	-30 000,00 AUD	-180 000,00 AUD
2003	1,28 milj. AUD	-580 000,00 AUD	-1,34 milj. AUD
2004	630 000,00 AUD	-690 000,00 AUD	-1,13 milj. AUD
2005	370 000,00 AUD	-2,27 milj. AUD	-3,13 milj. AUD
2006	190 000,00 AUD	-3,52 milj. AUD	-10,22 milj. AUD
2007	30 000,00 AUD	700 000,00 AUD	-11,09 milj. AUD
2008	5,88 milj. AUD	4,85 milj. AUD	3,16 milj. AUD
2009	6,93 milj. AUD	5,78 milj. AUD	3,76 milj. AUD
2010	1,46 milj. AUD	480 000,00 AUD	-1,61 milj. AUD
2011	200 000,00 AUD	-1,03 milj. AUD	-1,56 milj. AUD
2012	300 000,00 AUD	-590 000,00 AUD	-10,45 milj. AUD
2013	10 000,00 AUD	-610 000,00 AUD	-10,52 milj. AUD
2014	0 AUD	0 AUD	0 AUD
2015	0 AUD	0 AUD	0 AUD
2016	0 AUD	-130 000,00 AUD	-2,84 milj. AUD
2017	4200,00 AUD	-2,59 milj. AUD	-2,60 milj. AUD
2018	7210,00 AUD	-1,92 milj. AUD	-1,82 milj. AUD
2019	8730,00 AUD	-1,77 milj. AUD	-1,72 milj. AUD
2020	98 390,00 AUD	-2,33 milj. AUD	-3,25 milj. AUD
2021	510 980,00 AUD	-6,59 milj. AUD	-11,15 milj. AUD

2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
2,00	1,00	0	0	0	0	5,00	6,00	1,00	0	0	0	0	0	0	0	0	0	0	0
-	-50,00	-	-	-	-	-	20,00	-83,33	-	-	-	-	-	-	-	-	-	-	-
50,00	100,00	-	-	-	-	20,00	16,67	100,00	-	-	-	-	-	-	-	-	-	-	-
1000,00	1000,00	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-1,00	-1,00	-3,00	-10,00	-11,00	3,00	3,00	-1,00	-1,00	-10,00	-10,00	0	0	-2,00	-2,00	-1,00	-1,00	-3,00	-11,00
-	-	-	200,00	233,33	10,00	-127,27	-	-133,33	-	900,00	-	-	-	-	-	-50,00	-	200,00	266,67
9,57	12,81	15,63	23,33	34,45	40,81	41,62	67,56	83,24	100,53	113,01	113,01	0	0	248,47	18,97	23,90	41,77	45,45	77,27
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021

1,30	1,16	0,37	2,86	0,13	0,51	2,36	15,76	1,96	1,77	0,74	0,21	0,03	1,73	3,12	0,67	1,45	7,56	7,33	5,00
0,03	0,02	0,05	0,24	0,06	0,01	0,10	0,01	5,37	0	0	0	0,02	0,00	0,08	0,03	0,00	0,06	0,02	0,22
100,00	60,00	220,00	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	47,50
0	0	0,23	0,13	0,17	2,26	0,03	0	0,01	0,02	0,23	0,03	0	0	0	0	0,00	0,01	0,03	0,38
1,43	1,24	0,87	3,23	0,36	2,78	2,49	15,77	7,34	1,79	0,97	0,24	0,05	1,74	3,20	0,70	1,45	7,63	7,37	5,65
0,14	0,20	0,14	0,50	0,32	0,01	0,01	0,01	0,01	0	0	0	0	0	0,01	0	0	0	0	1,73
0	0	0	0,35	0	0	3,63	4,18	12,25	25,05	15,30	3,97	2,76	0,11	0,08	0,03	0	0	0	0
0,01	0,01	0,01	4,26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	15,12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11,03
1,30	1,22	2,50	9,11	11,91	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1,45	1,43	2,65	14,22	12,23	0,01	3,64	4,19	12,26	25,05	15,30	3,97	2,76	0,11	0,09	0,03	0	0	0	27,87
2,88	2,67	3,52	17,45	12,59	2,79	6,13	19,96	19,60	26,84	16,27	4,21	2,81	1,85	3,29	0,73	1,45	7,63	7,37	33,52

16,05	17,56	18,99	36,21	39,37	41,35	41,35	50,55	50,55	60,04	60,04	60,04	60,04	61,54	6,62	6,65	9,30	16,98	19,29	51,83
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-13,74	-15,09	-16,22	-19,34	-28,32	-38,88	-35,68	-31,91	-33,52	-35,07	-45,52	-56,04	-59,15	-59,78	-3,75	-6,35	-8,13	-9,79	-12,75	-22,75
0	0	0	0	0	-420,00	0	0	0	0	550,00	-1100,00	0	0	-41,27	-38,09	-42,72	-56,02	-62,91	-22,83
0	0	0	0	0	0	0	0,38	1,85	1,64	0,03	0,02	0	0	0	0	0	0	0	0
2,31	2,47	2,77	16,87	11,05	2,05	5,67	19,02	18,88	26,61	15,10	2,92	0,89	1,76	2,83	0,26	1,13	7,13	6,48	29,06
340,00	90,00	690,00	500,00	800,00	120,00	450,00	320,00	60,00	100,00	130,00	140,00	90,00	66,37	368,98	422,95	238,21	427,71	798,86	762,14
10,00	20,00	40,00	60,00	50,00	130,00	20,00	10,00	10,00	20,00	20,00	10,00	30,00	24,05	20,22	35,73	62,39	35,49	77,08	350,36
0	0	0	0	0	0	0	600,00	640,00	120,00	40,00	10,00	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1,00	1,16	1,82	0	0,07	0	0	0	0	0
0	0	0	0	710,00	490,00	0	0	0	0	0	0	0	0	0	0	0	0	0	346,63
0,35	0,11	0,73	0,56	1,56	0,74	0,47	0,93	0,71	0,24	1,19	1,32	1,94	0,09	0,46	0,46	0,30	0,46	0,88	1,46
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	917,50
0,19	0,07	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,06
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10,28	22,04	28,66	23,19	29,82
0,19	0,07	0	0	0	0	0	0	0	0	0	0	0	0	0	0,01	0,02	0,03	0,02	3,01
0,54	0,18	0,73	0,56	1,56	0,74	0,47	0,93	0,71	0,24	1,19	1,32	1,94	0,09	0,46	0,47	0,32	0,49	0,90	4,46
2,85	2,65	3,50	17,43	12,61	2,79	6,14	19,95	19,59	26,85	16,29	4,24	2,83	1,85	3,29	0,73	1,45	7,63	7,37	33,52

2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016	2017	2018	2019	2020	2021
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	-1000,00	-2000,00	0	0	0	0	0	0	0	0	0	0	0	0	0	1000,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-1,00	0	-4,00	-5,00	-3,00	0	0	0	-1,00	0	0	0	0	-2,00	-1,00	-1,00	-2,00	-5,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-1,00	0	-1,00	-5,00	-1,00	2,00	1,00	5,00	-12,00	0	0	0	2,00	0	0	0	0	0	2,00
0	0	-1,00	-4,00	-1,00	2,00	1,00	5,00	-12,00	0	0	0	2,00	0	0	0	0	0	3,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1000,00	0	-2000,00	0	0	0	0	0	0
2,00	1,00	1,00	13,00	3,00	1,00	0	0	0	0	0	0	0	3,00	0	2,00	8,00	2,00	0
2,00	1,00	1,00	12,00	3,00	1,00	0	9,00	0	0	0	0	0	2,00	0	2,00	7,00	2,00	0
0	0	0	-1,00	0	0	0	9,00	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	-1,00	0	-5,00	-2,00	0	12,00	-14,00	-1,00	-1,00	-1,00	0	2,00	-4,00	-1,00	4,00	-3,00	-8,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

BARD1 Life Sciences Brutomarža	BARD1 Life Sciences Peļņas marge	BARD1 Life Sciences EBIT marža	BARD1 Life Sciences Peļņas marge
2021	87,47 %	-1290,51 %	-2182,25 %
2020	87,47 %	-2370,73 %	-3306,79 %
2019	87,47 %	-20 305,96 %	-19 670,91 %
2018	87,47 %	-26 624,55 %	-25 205,27 %
2017	87,47 %	-61 721,43 %	-62 004,05 %
2016	87,47 %	0 %	0 %
2015	87,47 %	0 %	0 %
2014	87,47 %	0 %	0 %
2013	87,47 %	-6100,00 %	-105 200,01 %
2012	87,47 %	-196,67 %	-3483,33 %
2011	87,47 %	-515,00 %	-780,00 %
2010	87,47 %	32,88 %	-110,27 %
2009	87,47 %	83,41 %	54,26 %
2008	87,47 %	82,48 %	53,74 %
2007	87,47 %	2333,33 %	-36 966,67 %
2006	47,37 %	-1852,63 %	-5378,95 %
2005	89,19 %	-613,51 %	-845,95 %
2004	84,13 %	-109,52 %	-179,37 %
2003	86,72 %	-45,31 %	-104,69 %
2002	84,89 %	-1,33 %	-8,00 %

	Brutomarža	EBIT marža	Peļņas marge
2002	84,89 %	-1,33 %	-8,00 %
2003	86,72 %	-45,31 %	-104,69 %
2004	84,13 %	-109,52 %	-179,37 %
2005	89,19 %	-613,51 %	-845,95 %
2006	47,37 %	-1852,63 %	-5378,95 %
2007	87,47 %	2333,33 %	-36 966,67 %
2008	87,47 %	82,48 %	53,74 %
2009	87,47 %	83,41 %	54,26 %
2010	87,47 %	32,88 %	-110,27 %
2011	87,47 %	-515,00 %	-780,00 %
2012	87,47 %	-196,67 %	-3483,33 %
2013	87,47 %	-6100,00 %	-105 200,01 %
2014	87,47 %	0 %	0 %
2015	87,47 %	0 %	0 %
2016	87,47 %	0 %	0 %
2017	87,47 %	-61 721,43 %	-62 004,05 %
2018	87,47 %	-26 624,55 %	-25 205,27 %
2019	87,47 %	-20 305,96 %	-19 670,91 %
2020	87,47 %	-2370,73 %	-3306,79 %
2021	87,47 %	-1290,51 %	-2182,25 %

Datums	BARD1 Life Sciences Apgrozījums uz vienu akciju	BARD1 Life Sciences EBIT uz vienu akciju	BARD1 Life Sciences Peļņa uz vienu akciju
2021	0,01 undefined	-0,09 undefined	-0,14 undefined
2020	0,00 undefined	-0,05 undefined	-0,07 undefined
2019	0,00 undefined	-0,04 undefined	-0,04 undefined
2018	0,00 undefined	-0,08 undefined	-0,08 undefined
2017	0,00 undefined	-0,14 undefined	-0,14 undefined
2016	0 undefined	-0,00 undefined	-0,01 undefined
2015	0 undefined	0 undefined	0 undefined
2014	0 undefined	0 undefined	0 undefined
2013	0,00 undefined	-0,01 undefined	-0,09 undefined
2012	0,00 undefined	-0,01 undefined	-0,09 undefined
2011	0,00 undefined	-0,01 undefined	-0,02 undefined
2010	0,02 undefined	0,01 undefined	-0,02 undefined
2009	0,10 undefined	0,09 undefined	0,06 undefined
2008	0,14 undefined	0,12 undefined	0,08 undefined
2007	0,00 undefined	0,02 undefined	-0,27 undefined
2006	0,01 undefined	-0,10 undefined	-0,30 undefined
2005	0,02 undefined	-0,10 undefined	-0,13 undefined
2004	0,04 undefined	-0,04 undefined	-0,07 undefined
2003	0,10 undefined	-0,05 undefined	-0,10 undefined
2002	0,24 undefined	-0,00 undefined	-0,02 undefined

	Apgrozījums uz vienu akciju	EBIT uz vienu akciju	Peļņa uz vienu akciju
2002	0,24 AUD	-0,00 AUD	-0,02 AUD
2003	0,10 AUD	-0,05 AUD	-0,10 AUD
2004	0,04 AUD	-0,04 AUD	-0,07 AUD
2005	0,02 AUD	-0,10 AUD	-0,13 AUD
2006	0,01 AUD	-0,10 AUD	-0,30 AUD
2007	0,00 AUD	0,02 AUD	-0,27 AUD
2008	0,14 AUD	0,12 AUD	0,08 AUD
2009	0,10 AUD	0,09 AUD	0,06 AUD
2010	0,02 AUD	0,01 AUD	-0,02 AUD
2011	0,00 AUD	-0,01 AUD	-0,02 AUD
2012	0,00 AUD	-0,01 AUD	-0,09 AUD
2013	0,00 AUD	-0,01 AUD	-0,09 AUD
2014	0 AUD	0 AUD	0 AUD
2015	0 AUD	0 AUD	0 AUD
2016	0 AUD	-0,00 AUD	-0,01 AUD
2017	0,00 AUD	-0,14 AUD	-0,14 AUD
2018	0,00 AUD	-0,08 AUD	-0,08 AUD
2019	0,00 AUD	-0,04 AUD	-0,04 AUD
2020	0,00 AUD	-0,05 AUD	-0,07 AUD
2021	0,01 AUD	-0,09 AUD	-0,14 AUD

	Akciju skaits
2002	9,57 milj. Aktien
2003	12,81 milj. Aktien
2004	15,63 milj. Aktien
2005	23,33 milj. Aktien
2006	34,45 milj. Aktien
2007	40,81 milj. Aktien
2008	41,62 milj. Aktien
2009	67,56 milj. Aktien
2010	83,24 milj. Aktien
2011	100,53 milj. Aktien
2012	113,01 milj. Aktien
2013	113,01 milj. Aktien
2014	113,01 milj. Aktien
2015	113,01 milj. Aktien
2016	248,47 milj. Aktien
2017	18,97 milj. Aktien
2018	23,90 milj. Aktien
2019	41,77 milj. Aktien
2020	45,45 milj. Aktien
2021	77,27 milj. Aktien

%	Nosaukums	Akcijas	Izmaiņas	Datums
14,50317 %	Merchant Funds Management Pty Ltd	11 610 762	-25 596	24.08.2021.
5,44572 %	Moggs Creek Proprietary Ltd.	4 359 667	1 659 667	13.08.2020.
5,09639 %	Irminger-Finger (Irmgard)	4 080 000	-40 000	29.07.2021.
1,50260 %	Traoj Pty. Ltd.	1 202 933	1 202 933	13.08.2020.
1,38059 %	Neate (David)	1 105 257	1 105 257	13.08.2020.
1,28524 %	Walker (Tony Michael)	1 028 918	0	13.08.2020.
1,24596 %	Rodgers (John Andrew)	997 474	619 048	13.08.2020.
1,05587 %	Emmanuel (Jeffrey Gerard)	845 294	-2 660 678	26.02.2021.
0,96990 %	Supergun Pty. Ltd.	776 468	0	13.08.2020.
0,95765 %	Ajava Holdings Pty. Ltd.	766 667	433 334	13.08.2020.
0,69559 %	Worldwise Enterprises Pty Ltd	556 865	20 593	13.08.2020.
0,68943 %	Wagner (Nathan Ryan)	551 937	551 937	13.08.2020.
0,64954 %	Laws (Barrie Ernest)	520 000	520 000	13.08.2020.
0,64538 %	Wilks (Lynne Maree)	516 667	129 334	13.08.2020.
0,63150 %	IFM Pty. Ltd.	505 556	505 556	13.08.2020.
0,62456 %	Hancock (Russell Kay)	500 000	500 000	13.08.2020.
0,57626 %	Pelagyia Pty. Ltd.	461 333	461 333	13.08.2020.
0,50503 %	Johnston (Max)	404 310	93 021	24.08.2021.
0,40800 %	Powell (Philip)	326 631	40 000	21.10.2021.
0,18043 %	Cumming (Geoffrey James Ph.D.)	144 447	19 354	24.08.2021.
0 %	Gunzburg (Peter Lynton)	0	-1 312 740	28.07.2020.

What values and corporate philosophy does BARD1 Life Sciences represent?

BARD1 Life Sciences Ltd represents values of innovation, excellence, and integrity. With a strong corporate philosophy focused on advancing the field of precision medicine, BARD1 Life Sciences Ltd seeks to improve patient outcomes through the development of diagnostic tests for early cancer detection. The company has a commitment to conducting research that contributes to the understanding of cancer biology and the identification of novel biomarkers. BARD1 Life Sciences Ltd places great importance on collaboration with leading institutions and industry partners to accelerate the translation of scientific discoveries into clinical practice. With a dedicated team, BARD1 Life Sciences Ltd strives to make a positive impact in the fight against cancer.

In which countries and regions is BARD1 Life Sciences primarily present?

BARD1 Life Sciences Ltd is primarily present in Australia.

What significant milestones has the company BARD1 Life Sciences achieved?

BARD1 Life Sciences Ltd has achieved several significant milestones. The company has successfully developed a novel and highly specific cancer diagnostic test, known as BARD1 Ovarian Cancer Test, which has shown promising results in early detection and monitoring of ovarian cancer. BARD1 has also established collaborations with renowned research institutions and pharmaceutical companies to further develop their portfolio of diagnostic and therapeutic products. The company has received recognition and grants for its innovative research and has secured partnerships to expand its global reach. BARD1 Life Sciences Ltd is committed to making impactful contributions to the field of cancer detection and treatment.

What is the history and background of the company BARD1 Life Sciences?

BARD1 Life Sciences Ltd is a biotechnology company based in Australia. Established in 2004, BARD1 focuses on developing and commercializing innovative diagnostics and therapeutics for cancer. The company is engaged in the research and development of novel diagnostic tests that detect specific cancer biomarkers. With a strong emphasis on early cancer detection and personalized medicine, BARD1 aims to improve patient outcomes through its cutting-edge technologies. The company has a dedicated team of scientists and researchers who work tirelessly to advance their product pipeline. BARD1 Life Sciences Ltd is committed to making a significant impact in the field of cancer diagnostics and improving the lives of patients worldwide.

Who are the main competitors of BARD1 Life Sciences in the market?

The main competitors of BARD1 Life Sciences Ltd in the market include other companies operating in the field of life sciences and diagnostics. Some notable competitors include companies like Illumina Inc., Thermo Fisher Scientific Inc., and QIAGEN N.V. These companies, like BARD1 Life Sciences Ltd, are engaged in the development and commercialization of innovative diagnostic tests and technologies. Their competition fosters continuous innovation and drives advancements in the life sciences industry.

In which industries is BARD1 Life Sciences primarily active?

BARD1 Life Sciences Ltd is primarily active in the biotechnology and life sciences industries.

What is the business model of BARD1 Life Sciences?

The business model of BARD1 Life Sciences Ltd is focused on the development and commercialization of cancer diagnostics and therapeutics. Specializing in precision oncology, BARD1 aims to identify and develop innovative biomarkers and companion diagnostics for early detection and personalized treatment of various cancers. By leveraging its proprietary technology and strategic collaborations, BARD1 Life Sciences is committed to improving patient outcomes and providing advancements in the field of cancer management.

Kāds ir BARD1 Life Sciences 2024 KGV?

Pašreizējais KGV BARD1 Life Sciences nevar tikt aprēķināts.

Kāds ir BARD1 Life Sciences 2024 KUV?

KUV šobrīd BARD1 Life Sciences nevar aprēķināt.

Kāds AlleAktien kvalitātes vērtējums ir BARD1 Life Sciences?

AlleAktien kvalitātes vērtējums BARD1 Life Sciences ir 5/10.

Cik liels ir BARD1 Life Sciences 2024 apgrozījums?

Pašreiz nevar aprēķināt apgrozījumu BARD1 Life Sciences.

Cik liels ir BARD1 Life Sciences 2024 peļņa?

Pašlaik peļņa BARD1 Life Sciences nevar tikt aprēķināta.

Kas ir BARD1 Life Sciences?

The BARD1 Life Sciences Ltd is an Australian biotechnology company specializing in the development of innovative cancer therapies. It focuses on the research and development of diagnostic and therapeutic products for various types of cancer. The company works closely with leading scientists and universities to develop and explore new products. One of the main divisions of BARD1 Life Sciences is the exploration of biomarker-based test procedures for early cancer detection. It develops innovative concepts to create fast, reliable, objective, and affordable diagnostic platforms. The products include tests for breast, cervical, prostate, and colon cancer. Another important area of BARD1 Life Sciences' business is the development of therapies for cancer patients. The company has developed a highly advanced drug discovery platform and collaborates closely with leading research institutions. The products range from immunotherapies to targeted therapies and chemotherapy. An important milestone in the history of BARD1 Life Sciences was the discovery of a new cancer gene called BARD1. The company found a new way to fight cancer through this discovery. The BARD1 gene is a tumor suppressor gene that malfunctions in many different types of cancer. The company has acquired exclusive rights to use this gene for diagnostic and therapeutic purposes. BARD1 Life Sciences has also formed partnerships with major pharmaceutical companies such as Bio-Rad Laboratories and Daiichi Sankyo to support product marketing and distribution. The company has also filed patents for several of its products to protect its innovations. The business model of BARD1 Life Sciences is based on the development of innovative products to improve cancer diagnosis and therapy. The different divisions include both diagnostics and therapeutics. The use of the BARD1 gene gives the company a unique competitive advantage and helps differentiate its products from those of competitors. Overall, BARD1 Life Sciences has established itself in the biotechnology industry and is working hard to develop new products that advance cancer research and improve patient care. With a strong pipeline of products and a growing number of partnerships, the company is well positioned to continue offering innovative solutions for cancer treatment.

Cik liela ir BARD1 Life Sciences dividende?

BARD1 Life Sciences izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Cik bieži BARD1 Life Sciences maksā dividendes?

Dividendes pašlaik nevar aprēķināt BARD1 Life Sciences vai uzņēmums nedod dividendes.

Kas ir BARD1 Life Sciences ISIN?

BARD1 Life Sciences ISIN ir AU000000BD12.

Kas ir BARD1 Life Sciences WKN?

BARD1 Life Sciences WKN ir A2AL50.

Kas ir BARD1 Life Sciences biržas kods?

BARD1 Life Sciences simbols ir BD1.AX.

Cik lielu dividendēm maksā BARD1 Life Sciences?

Pēdējo 12 mēnešu laikā BARD1 Life Sciences maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos BARD1 Life Sciences plāno maksāt dividendes 0 AUD apmērā.

Cik augsta ir BARD1 Life Sciences dividendu rentabilitāte?

BARD1 Life Sciences pašreizējā dividendu rentabilitāte ir .

Kad BARD1 Life Sciences maksā dividendes?

BARD1 Life Sciences maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Cik droša ir BARD1 Life Sciences dividende?

BARD1 Life Sciences pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Cik liela ir BARD1 Life Sciences dividende?

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

Kurā sektorā atrodas BARD1 Life Sciences?

BARD1 Life Sciences tiek piešķirts nozarei "Veselība".

Wann musste ich die Aktien von BARD1 Life Sciences kaufen, um die vorherige Dividende zu erhalten?

Lai saņemtu pēdējo dividendu BARD1 Life Sciences apmērā 0 AUD, kas tika izmaksāta 27.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.11.2024..

Kad BARD1 Life Sciences izmaksāja pēdējo dividendē?

Pēdējās dividendes izmaksa notika 27.11.2024..

Cik liela bija BARD1 Life Sciences dividende gadā 2023?

Gadā 2023, BARD1 Life Sciences izmaksāja 0 AUD dividendes.

Kādā valūtā BARD1 Life Sciences izmaksā dividendes?

BARD1 Life Sciences dividendes tiek izmaksātas AUD.

BARD1 Life Sciences Akciju biržas simbols	BARD1 Life Sciences FIGI
EUG:EO	BBG000QB5ZX7
EUG:E1	BBG000QB6535
EUGEUR:EO	BBG00D3DBFW8
EUGEUR:XJ	BBG00D3DBG47
EUGEUR:XS	BBG00D3DBGC8
EUGEUR:E1	BBG00D3DBGF5
EUG:XX	BBG00JN77BK3
EUGEUR:XX	BBG00JN8HXN9
EUG:EP	BBG00RCXXPQ4
EUG:EZ	BBG00RCXXPS2

Veic labākos ieguldījumus savā dzīvē

Kurss

Akciju cena

SimbolsBD1.AX

ISINAU000000BD12

WKNA2AL50

BARD1 Life Sciences akciju kurss

Kurs

Pārskats

Intraday funkcija

Kopējais atdevē un relatīvās cenas izmaiņas

Interpretācija un ieguldījumi

BARD1 Life Sciences Akciju vēsture

BARD1 Life Sciences Akcijas apgrozījums, EBIT, peļņa AU000000BD12 · A2AL50

Apgrozījums, peļņa & EBIT

Apgrozījuma, EBIT un ienākumu izpratne

Gada analīze un salīdzinājumi

Ieguvumu izmantošana investīcijām

Ieguldījumu ieskati

BARD1 Life Sciences Apjoma, peļņas un EBIT vēsture

BARD1 Life Sciences Akciju Rādītāji

Peļņas un zaudējumu pārskats

Apjomi un izaugsme

Bruto marža

EBIT un EBIT marža

Ienākumi un izaugsme

Izlaistās akcijas

Gadskārtējās salīdzinājuma interpretācija

Gaidījumi un prognozes

Bilance

Bilances izpratne

Aktīvi

Parādsaistības

Pašu kapitāls

Gadu pēc gada analīze

Datu interpretācija

BARD1 Life Sciences akcijas maržas AU000000BD12 · A2AL50

Maržas

Brutomaržas izpratne

EBIT maržas analīze

Apjoma maržas ieskati

Gaidāmo vērtību interpretēšana

Salīdzinošā analīze

BARD1 Life Sciences Maržas vēsture

BARD1 Life Sciences akciju apgrozījums, EBIT, peļņa uz vienu akciju AU000000BD12 · A2AL50

Apjoms, EBIT un Peļņa uz vienu akciju

Apjoms uz vienu akciju

EBIT uz vienu akciju

Ienākumi uz vienu akciju

Gaidāmās vērtības

BARD1 Life Sciences Apjoma, peļņas un EBIT vēsture uz vienu akciju

BARD1 Life Sciences akcija un akciju analīze

Veic labākos ieguldījumus savā dzīvē

BARD1 Life Sciences vērtējums pēc Fair Value

Fair Value

Fair Value izpratne

Ienākumu bāzes Fair Value

Apgrozījuma bāzes Fair Value

Dividende bāzes Fair Value

Gaidas un prognozes

Salīdzinošā analīze

BARD1 Life Sciences vērtējums pēc vēsturiskā PE, EBIT un P/S

Veic labākos ieguldījumus savā dzīvē

BARD1 Life Sciences akciju skaits AU000000BD12 · A2AL50

Apjoms, EBIT un Peļņa uz vienu akciju

Apjoms uz vienu akciju

EBIT uz vienu akciju

Ienākumi uz vienu akciju

Gaidāmās vērtības

BARD1 Life Sciences Akciju spliti

Veic labākos ieguldījumus savā dzīvē

BARD1 Life Sciences Peļņas prognozes

BARD1 Life Sciences Pelnīguma Pārsteigumi

BARD1 Life Sciences Akciju akcionāru struktūra

Bieži uzdotie jautājumi par BARD1 Life Sciences akciju

What values and corporate philosophy does BARD1 Life Sciences represent?

In which countries and regions is BARD1 Life Sciences primarily present?

What significant milestones has the company BARD1 Life Sciences achieved?

What is the history and background of the company BARD1 Life Sciences?

Who are the main competitors of BARD1 Life Sciences in the market?

Simbols
BD1.AX

ISIN
AU000000BD12

WKN
A2AL50